Insulin glargine

Application:LG100754 (UVI 2112) is a modulator of RXR dimers. LG100754 acts as an antagonist of the homodimeric RXR:RXR, but as an agonist of the heterodimeric RXR:PPARα and RXR:PPARγ. LG100754 is an insulin sensitizer acting through RXR.

Application:LG100754 (UVI 2112) is a modulator of RXR dimers. LG100754 acts as an antagonist of the homodimeric RXR:RXR, but as an agonist of the heterodimeric RXR:PPARα and RXR:PPARγ. LG100754 is an insulin sensitizer acting through RXR.

Application:LG100754 (UVI 2112) is a modulator of RXR dimers. LG100754 acts as an antagonist of the homodimeric RXR:RXR, but as an agonist of the heterodimeric RXR:PPARα and RXR:PPARγ. LG100754 is an insulin sensitizer acting through RXR.

Application:LG100754 (UVI 2112) is a modulator of RXR dimers. LG100754 acts as an antagonist of the homodimeric RXR:RXR, but as an agonist of the heterodimeric RXR:PPARα and RXR:PPARγ. LG100754 is an insulin sensitizer acting through RXR.

Application:LG100754 (UVI 2112) is a modulator of RXR dimers. LG100754 acts as an antagonist of the homodimeric RXR:RXR, but as an agonist of the heterodimeric RXR:PPARα and RXR:PPARγ. LG100754 is an insulin sensitizer acting through RXR.

Application:LG100754 (UVI 2112) is a modulator of RXR dimers. LG100754 acts as an antagonist of the homodimeric RXR:RXR, but as an agonist of the heterodimeric RXR:PPARα and RXR:PPARγ. LG100754 is an insulin sensitizer acting through RXR.

LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40) , with EC 50 s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with

LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40) , with EC 50 s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with

LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40) , with EC 50 s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with

LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40) , with EC 50 s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with

LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40) , with EC 50 s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with

Macaque (Primate) Pituitary GenLysate™